Mechanisms of plaque stabilization with statins.

[1]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[2]  P. Libby,et al.  Lipid Lowering Reduces Oxidative Stress and Endothelial Cell Activation in Rabbit Atheroma , 2002, Circulation.

[3]  J. Liao.  Isoprenoids as mediators of the biological effects of statins. , 2002, The Journal of clinical investigation.

[4]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[5]  P. Serruys,et al.  Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.

[6]  P. Ridker,et al.  Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia. , 2002, The American journal of cardiology.

[7]  T. Lüscher,et al.  Statin Prevents Tissue Factor Expression in Human Endothelial Cells: Role of Rho/Rho-Kinase and Akt Pathways , 2002, Circulation.

[8]  A. Keech,et al.  Relationship Between Lipid Levels and Clinical Outcomes in the Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID) Trial: To What Extent Is the Reduction in Coronary Events With Pravastatin Explained by On-Study Lipid Levels? , 2002, Circulation.

[9]  P. Libby,et al.  Inflammation and Atherosclerosis , 2002, Circulation.

[10]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[11]  M Schartl,et al.  Use of Intravascular Ultrasound to Compare Effects of Different Strategies of Lipid-Lowering Therapy on Plaque Volume and Composition in Patients With Coronary Artery Disease , 2001, Circulation.

[12]  Peter Libby,et al.  Current Concepts of the Pathogenesis of the Acute Coronary Syndromes , 2001, Circulation.

[13]  N Rifai,et al.  Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. , 2001, JAMA.

[14]  Paul M. Ridker,et al.  Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. , 2001, The New England journal of medicine.

[15]  S. Grundy,et al.  Effect of Hydroxymethyl Glutaryl Coenzyme A Reductase Inhibitor Therapy on High Sensitive C-Reactive Protein Levels , 2001, Circulation.

[16]  Michael F. Oliver,et al.  Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study. , 2001, Indian heart journal.

[17]  P. Ridker,et al.  Rapid Reduction in C-Reactive Protein With Cerivastatin Among 785 Patients With Primary Hypercholesterolemia , 2001, Circulation.

[18]  Christopher K. Glass,et al.  Atherosclerosis The Road Ahead , 2001, Cell.

[19]  P. Shah,et al.  Pravastatin Treatment Increases Collagen Content and Decreases Lipid Content, Inflammation, Metalloproteinases, and Cell Death in Human Carotid Plaques: Implications for Plaque Stabilization , 2001, Circulation.

[20]  P. Libby,et al.  An HMG-CoA Reductase Inhibitor, Cerivastatin, Suppresses Growth of Macrophages Expressing Matrix Metalloproteinases and Tissue Factor In Vivo and In Vitro , 2001, Circulation.

[21]  R. Junker,et al.  Symptomatic Ischemic Stroke in Full-Term Neonates: Role of Acquired and Genetic Prothrombotic Risk Factors , 2000, Stroke.

[22]  M. Endres,et al.  Atorvastatin Upregulates Type III Nitric Oxide Synthase in Thrombocytes, Decreases Platelet Activation, and Protects From Cerebral Ischemia in Normocholesterolemic Mice , 2000, Stroke.

[23]  P. Libby,et al.  HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[24]  M. Linton,et al.  Current perspectives on statins. , 2000, Circulation.

[25]  J. Larosa,et al.  Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. , 1999, JAMA.

[26]  P. Libby,et al.  Dietary lipid lowering reduces tissue factor expression in rabbit atheroma. , 1999, Circulation.

[27]  M. Pfeffer,et al.  Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein , 1999 .

[28]  P. Libby,et al.  Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. , 1999, Circulation.

[29]  P. Libby,et al.  Lipid lowering promotes accumulation of mature smooth muscle cells expressing smooth muscle myosin heavy chain isoforms in rabbit atheroma. , 1998, Circulation research.

[30]  M. Moskowitz,et al.  Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[31]  P. Libby,et al.  Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. , 1998, Circulation.

[32]  G. Thorgeirsson,et al.  Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S) , 1998, Circulation.

[33]  P. Macfarlane,et al.  Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). , 1998, Circulation.

[34]  B. Davis,et al.  Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. , 1998, Circulation.

[35]  U. Laufs,et al.  Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. , 1998, Circulation.

[36]  H. Lennernäs,et al.  Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase Inhibitors , 1997, Clinical pharmacokinetics.

[37]  E. Tremoli,et al.  Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[38]  Fuster,et al.  Hemostasis, thrombosis, fibrinolysis, and cardiovascular disease , 1997 .

[39]  Y. Tsujita,et al.  Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques. Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[40]  M. Ferguson,et al.  Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. , 1995, Circulation.

[41]  P. Libby,et al.  Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. , 1994, The Journal of clinical investigation.

[42]  V. Fuster,et al.  Macrophage Infiltration in Acute Coronary Syndromes: Implications for Plaque Rupture , 1994, Circulation.

[43]  S. Manuck,et al.  Plaque changes and arterial enlargement in atherosclerotic monkeys after manipulation of diet and social environment. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[44]  A. Henney,et al.  Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. , 1991, Proceedings of the National Academy of Sciences of the United States of America.